{"id":"W3174459433","doi":"10.1016/j.eucr.2021.101762","title":"Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Urology Case Reports","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University of British Columbia; Surrey Place Centre; Surrey Memorial Hospital","funders":"Canadian Institutes of Health Research; Bladder Cancer Canada; Astellas Pharma Canada; Merck; Janssen Pharmaceuticals; AstraZeneca","keywords":"Durvalumab; Medicine; Urothelial cancer; Immune checkpoint; Bladder cancer; Tremelimumab; Metastatic Urothelial Carcinoma; Avelumab; Oncology; Immunotherapy; Disease; Missense mutation; Cancer research; Cancer; Internal medicine; Urothelial carcinoma; Mutation; Nivolumab; Ipilimumab; Gene; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000678259,0.0008586703,0.001246197,0.001505771,0.001497184,0.00162808,0.001123071,0.002921394,0.002587734],"category_scores_gemma":[0.003728118,0.0005481367,0.001474161,0.0009923375,0.001257106,0.001023633,0.001691438,0.002814743,0.0008666409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00115172,"about_ca_system_score_gemma":0.0007084416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00145554,"about_ca_topic_score_gemma":0.002049939,"domain_scores_codex":[0.999006,0.0001774146,0.00009348167,0.0001771548,0.0002013069,0.0003447686],"domain_scores_gemma":[0.996546,0.0007402787,0.0007996691,0.0004948467,0.0002286325,0.001190602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"case_report","study_design_scores_codex":[0.00006312898,0.00002949994,0.00756342,0.00006181876,0.00001893739,0.9870955,0.0001362714,0.0001178255,0.001209596,0.0002558004,0.0003509667,0.003097146],"study_design_scores_gemma":[0.000009955683,0.00008042563,0.005240519,0.00001581957,0.00001638187,0.9919241,0.00006625305,0.0003410669,0.00135234,0.0001517664,0.0007936787,0.00000768764],"study_design_candidate":"case_report","study_design_consensus":"case_report","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9597731,0.006933255,0.006940555,0.00402049,0.0005062331,0.0002876841,0.0003168881,0.000574818,0.02064699],"genre_scores_gemma":[0.9958504,0.0008386184,0.0007567295,0.0007567772,0.0002428626,0.00001853044,0.0000974187,0.0000328525,0.001405699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002921394,"threshold_uncertainty_score":0.008656859,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02128113715824269,"score_gpt":0.277644438413306,"score_spread":0.2563633012550633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}